All raw data obtained in the two clinical trials described are included in [S1 Appendix](#pmed.1003203.s025){ref-type="supplementary-material"} (pilot study) and [S2 Appendix](#pmed.1003203.s026){ref-type="supplementary-material"} (comparative study).

Introduction {#sec008}
============

Resistance to artemisinin-based combination therapies---the first-line treatment for malaria---is spreading in the Greater Mekong subregion \[[@pmed.1003203.ref001]\] and is threatening malaria control. Artemisinin resistance is characterised by a delayed clearance phenotype, with a parasite clearance half-life \>5 hours \[[@pmed.1003203.ref002]\]. This drug-resistant phenotype is linked to a number of specific nonsynonymous mutations in the *Plasmodium falciparum kelch13* gene \[[@pmed.1003203.ref003],[@pmed.1003203.ref004]\]. New drugs to treat malaria infection with artemisinin-resistant (ART-R) parasites are needed.

The development of antimalarial drugs has been accelerated by volunteer infection studies (VIS), in which healthy volunteers are experimentally infected with malaria parasites to evaluate the efficacy of candidate antimalarial drugs \[[@pmed.1003203.ref005]\]. VIS allow early accrual of efficacy and dose-response data, thereby minimising the risk of failure when conducting phase 2 studies in patients with clinical malaria. The induced blood-stage malaria (IBSM) model, a type of VIS in which volunteers are inoculated with *Plasmodium*-infected erythrocytes \[[@pmed.1003203.ref006]--[@pmed.1003203.ref009]\], is particularly suitable to evaluate drug efficacy against blood-stage infection, the parasite stage that causes malaria morbidity and mortality. To date, the IBSM model has only been used with artemisinin-sensitive (ART-S) parasites, mainly with 3D7, the reference strain of *P*. *falciparum*.

Here, we present the results from 2 clinical trials. First, we conducted a pilot study in which we inoculated participants with ART-R *P*. *falciparum* parasites harbouring the *kelch13* gene mutation R539T (K13^R539T^ strain) \[[@pmed.1003203.ref004]\] to determine the safety, tolerability, and clearance of infection with ART-R parasites. Then, in a comparative study, we randomised participants to be inoculated with ART-R (K13^R539T^ strain) or ART-S (3D7 strain) parasites and compared the clearance profiles of these 2 parasite strains after administration of a single oral dose of artesunate (AS). We used single-dose AS monotherapy rather than a longer course of AS or artemisinin-based combination therapy because this study design provided the best opportunity to investigate the pharmacodynamic effect of AS alone on the clearance of ART-R and ART-S parasites without the confounding effect of a partner drug. Furthermore, we had previously observed that single-dose drug administration with subcurative intention is a very effective design for characterising the pharmacodynamic effect of an antimalarial drug \[[@pmed.1003203.ref007]\]. The aim of this study was to evaluate the safety and infectivity of ART-R parasites and to compare the parasitological response of the ART-R and ART-S parasites to AS in healthy participants inoculated in the IBSM model. We hypothesised that AS would clear parasitaemia from participants infected with ART-R parasites at a slower rate compared to participants infected with ART-S parasites, as observed in field studies \[[@pmed.1003203.ref002]\].

Methods {#sec009}
=======

Study design {#sec010}
------------

We conducted 2 consecutive phase 1, single-centre, open-label studies: a pilot study and a randomised study. In both studies, healthy participants were inoculated with ART-R parasites using the IBSM model. In the pilot study, 2 participants were inoculated with ART-R parasites with a 3-week interval in between. In the comparative study, participants were randomised to receive ART-R or ART-S parasites. The studies were conducted at Q-Pharm Pty Ltd, Brisbane, Australia, and approved by both the QIMR Berghofer and Australian Red Cross Blood Service Human Research Ethics Committees. The studies were registered with the Australian New Zealand Clinical Trials Registry: ACTRN12617000244303 and ACTRN12617001394336. Data were analysed according to the clinical trial protocols (pilot and comparative studies, [S1](#pmed.1003203.s025){ref-type="supplementary-material"} and [S2](#pmed.1003203.s026){ref-type="supplementary-material"} Appendices, respectively) and the statistical analysis plan (comparative study, [S2 Appendix](#pmed.1003203.s026){ref-type="supplementary-material"}), which was finalised before the data were locked for analysis.

Participants {#sec011}
------------

Healthy adults were eligible for the study if they met all eligibility criteria ([S1](#pmed.1003203.s001){ref-type="supplementary-material"} and [S2](#pmed.1003203.s002){ref-type="supplementary-material"} Texts). Briefly, participants were malaria naïve, males (pilot study), or males and nonpregnant females (comparative study), aged 18--55 years. All participants gave written informed consent before enrollment and were compensated financially for their involvement in this study.

Randomisation and masking {#sec012}
-------------------------

Randomisation schedules were generated using STATA release 13 (StataCorp LLC, [www.stata.com](http://www.stata.com)). Participants in the comparative study were to be randomised in a 2:1 ratio to receive either ART-R or ART-S parasites. However, because of recruitment limitations, 3 participants in each cohort were randomised to receive ART-S parasites and the remainder randomised to receive ART-R parasites. The study was open label.

Procedures {#sec013}
----------

The ART-R *P*. *falciparum* isolate (Cam3.II^R539T^, here referred to as the K13^R539T^ strain) was originally collected from a patient in Cambodia with natural malaria infection \[[@pmed.1003203.ref004]\]. The ART-R master cell bank was manufactured using a bioreactor system as previously described \[[@pmed.1003203.ref010]\] and characterised at the time of release ([S3 Text](#pmed.1003203.s003){ref-type="supplementary-material"}). Although the master cell bank was screened for blood-borne pathogens, the risk of pathogen transmission cannot be completely excluded with any blood transfusion, although the risk should be considerably lower than a single-unit blood transfusion in which the volume transfused is \>5 logs higher. In vitro drug resistance testing and the ring-stage survival assay confirmed the ART-R parasites were resistant to artemisinin and sensitive to piperaquine ([S3 Text](#pmed.1003203.s003){ref-type="supplementary-material"} and [S1 Table](#pmed.1003203.s011){ref-type="supplementary-material"}). ART-R (K13^R539T^ strain) and ART-S (3D7 strain) parasite inocula were produced using methods previously described \[[@pmed.1003203.ref009]\].

In the pilot study, participants were intravenously inoculated with approximately 2,800 viable ART-R parasite-infected erythrocytes on Day 0. In the comparative study, participants were intravenously inoculated with approximately 2,800 viable ART-R parasite-infected erythrocytes on Day 0, or with approximately 2,800 viable ART-S parasite-infected erythrocytes on Day 1. ART-R infected participants were inoculated a day earlier than ART-S infected participants so that parasites were at a similar stage of development at the time of AS administration (see [Results](#sec016){ref-type="sec"} section for more detail). Parasitaemia was monitored by quantitative PCR (qPCR) targeting the *P*. *falciparum* 18S rRNA gene \[[@pmed.1003203.ref011]\]. Gametocytaemia was monitored by reverse transcription qPCR (qRT-PCR) for female-specific *pfs25* mRNA and male-specific *pfMGET* mRNA \[[@pmed.1003203.ref012]\].

Single-dose oral AS (approximately 2 mg/kg; Guilin Pharmaceutical Shanghai Co. Ltd) was administered in tablet form on Day 9 in both studies. If recrudescence occurred after AS administration, participants received an oral dose of 120 mg dihydroartemisinin (DHA)/960 mg piperaquine phosphate (PQP, Eurartesim, Alfasigma S.p.A.; pilot study) or 960 mg PQP (PCI Pharma Services; comparative study). On approximately Day 26, or earlier if a second recrudescence occurred, all participants received a standard curative course, taken orally, of atovaquone/proguanil (A/P, Malarone, GlaxoSmithKline Australia Pty Ltd). Participants also received an oral dose of 45 mg primaquine (PQ, Primacin, Boucher & Muir Pty Ltd) to clear gametocytes at the end of the study (pilot study and comparative study Cohort 1) or on approximately Day 23 (comparative study cohorts 2 and 3). Transmissibility to mosquitoes was investigated in the comparative study as an exploratory objective; these results will be reported separately. Participants had regular follow-up visits until the End of Study visit on Day 90 ± 14 days (pilot study) or Day 28 ± 3 days (comparative study). [Fig 1](#pmed.1003203.g001){ref-type="fig"} illustrates the study design. The study procedures and timing of assessments are summarised in [S2](#pmed.1003203.s012){ref-type="supplementary-material"} and [S3](#pmed.1003203.s013){ref-type="supplementary-material"} Tables.

![Study design.\
(A) In the pilot study, participants were IV inoculated with approximately 2,800 viable ART-R parasite-infected erythrocytes on Day 0, followed by AS administration on Day 9. Participants were confined at the clinical site for 3 days, during which they were administered DHA/PQP on Day 11. A/P and PQ administration occurred on Day 26 with the End of Study visit on Day 90 ± 14 days. (B) In the comparative study, participants were IV inoculated with approximately 2,800 viable ART-R parasite-infected erythrocytes (Day 0) or with approximately 2,800 viable ART-S parasite-infected erythrocytes (Day 1) and administered AS on Day 9. PQP administration occurred on Day 11 for ART-R infected participants and between Days 15 and 20 for ART-S infected participants. In the comparative study, the majority of participants were followed up after the End of Study visit for qPCR and/or safety monitoring. The timings of A/P administration, PQ administration, and the End of Study visit are also shown. ART-R, artemisinin-resistant; ART-S, artemisinin-sensitive; A/P, atovaquone/proguanil; AS, artesunate; DHA/PQP, dihydroartemisinin/piperaquine phosphate; IV, intravenously; PQ, primaquine; qPCR, quantitative PCR](pmed.1003203.g001){#pmed.1003203.g001}

Development of parasitaemia was monitored daily from Day 3 (pilot study Participant 1) or Day 4 (pilot study Participant 2 and comparative study) until parasites were detected by qPCR, then twice daily until AS administration. Parasitaemia was measured post-AS at specified timepoints until 84 hours ([S4 Table](#pmed.1003203.s014){ref-type="supplementary-material"}), then twice daily, daily, or every second day until parasitaemia was low and stable, then 3 times per week until A/P administration, and at the end of the study.

Plasma concentrations of AS and its active metabolite DHA were measured in blood samples ([S4 Text](#pmed.1003203.s004){ref-type="supplementary-material"}) at the time points specified in the protocol.

Outcomes {#sec014}
--------

A primary outcome of both studies was safety and tolerability of infection with ART-R parasites (and of ART-S parasites in the comparative study only), determined by evaluating adverse events, physical examinations, vital signs, clinical biochemistry, haematology, and urinalysis. In the pilot study, another primary outcome was the infectivity of ART-R parasites, which was determined by the presence of parasites in inoculated participants as measured by qPCR. In the comparative study, another primary outcome was to compare parasite clearance profiles of ART-R and ART-S parasites after single-dose AS administration, which was determined by estimating the slope of parasite clearance curves, the parasite reduction ratio per 48 hours in the logarithmic scale (log~10~PRR~48~), and parasite clearance half-lives. Based on previous IBSM studies with ART-S parasites, AS clearance data from ART-R strains in the field \[[@pmed.1003203.ref002]\], and data from the pilot study, we hypothesised that mean parasite clearance after AS administration would be 30% slower for ART-R infected participants compared to ART-S infected participants \[[@pmed.1003203.ref013]\]. Both studies had the exploratory outcome to calculate the following pharmacokinetic parameters for AS and DHA: area under the concentration-time curve from time 0 to the last measurable concentration (AUC~0-last~); area under the concentration-time curve from time 0 to infinite time (AUC~0-∞~); maximum concentration (C~max~); time of C~max~ (t~max~); and elimination half-life (t~1/2~).

Statistical analysis {#sec015}
--------------------

The sample size of the comparative study was calculated with nQuery Advisor version 7.0 (Statsols, [www.statsols.com](http://www.statsols.com)). Satterthwaite *t* test of equal means but unequal variances was used to calculate sample size with a one-sided α = 0.05, an estimated 30% mean difference in parasite clearance slope between ART-R and ART-S parasites, and a power of 80%. The estimated sample size using a 2:1 ratio of ART-R to ART-S was 18 to 9 participants. Participants were to be enrolled in 3 cohorts of 9 participants each. Review of parasitaemia data between cohorts was conducted using an adaptive design to re-evaluate the sample size necessary to reach the primary outcomes.

The parasite clearance slope is the slope of the linear regression of log~10~ parasitemia over time after AS administration, derived from an iterative procedure \[[@pmed.1003203.ref013]\]. The weighted mean of the parasite clearance slope was estimated by the inverse-variance method using the corresponding standard errors of the clearance slope and presented as log~10~PRR~48~ and the parasite clearance half-life, as previously described \[[@pmed.1003203.ref013]\]. An omnibus test \[[@pmed.1003203.ref014]\] was used to determine differences between the weighted mean parasite clearance slopes of ART-R and ART-S parasites. Analyses were determined using R version 3.5.0.

Parasite growth dynamics were estimated using a sine-wave model to capture the oscillatory nature of the parasite growth \[[@pmed.1003203.ref015]\]. The sine-wave growth model was applied to the pre-AS qPCR data using R version 3.5.0 and R package nlme version 3.1--137. For the pilot study, the sine-wave growth model was estimated for each participant, and the life cycle duration of ART-R parasites was estimated from the inverse-variance weighted mean of the sine-wave period estimates ([S5 Text](#pmed.1003203.s005){ref-type="supplementary-material"}). For the comparative study, the parasite growth dynamics for ART-R and ART-S parasites were modelled using the sine-wave mixed-effects model ([S5 Text](#pmed.1003203.s005){ref-type="supplementary-material"}).

Pharmacokinetic parameters were determined by noncompartmental analysis using R version 3.4.2 and R package IQRtools version 0.9.1 (IntiQuan GmbH). Mann--Whitney *U* tests were used to compare pharmacokinetic parameters of ART-R and ART-S infected participants.

Results {#sec016}
=======

The pilot study (*n* = 2) was conducted from April 27, 2017 to September 12, 2017, and the comparative study (*n* = 25) from October 26, 2017 to October 18, 2018 ([Fig 2](#pmed.1003203.g002){ref-type="fig"}). In the comparative study, 25 participants were enrolled over 3 cohorts and randomised to receive ART-R (*n* = 16) ART-S (*n* = 9) parasites. Three participants randomised to ART-R parasites withdrew prior to inoculation, giving a final ratio of 13:9 ART-R to ART-S infected participants. No more participants were enrolled because the primary outcomes were met. All inoculated participants completed the study and were included in all final analyses. Participant baseline characteristics are summarised in [Table 1](#pmed.1003203.t001){ref-type="table"}.

![Clinical trial profile.\
In the pilot study, 2 participants were enrolled in 2 cohorts and inoculated with ART-R parasites, with a 3-week interval between cohorts (Cohort 1, *n* = 1; Cohort 2, *n* = 1). In the comparative study, 22 participants were inoculated with ART-R (*n* = 13) or ART-S (*n* = 9) parasites. Inoculated participants were enrolled in 3 cohorts: Cohort 1 (ART-R, *n* = 3; ART-S, *n* = 3), Cohort 2 (ART-R, *n* = 7; ART-S, *n* = 3), and Cohort 3 (ART-R, *n* = 3; ART-S, *n* = 3). ART-R, artemisinin-resistant; ART-S, artemisinin-sensitive.](pmed.1003203.g002){#pmed.1003203.g002}

10.1371/journal.pmed.1003203.t001

###### Participant baseline characteristics.

![](pmed.1003203.t001){#pmed.1003203.t001g}

  Participant characteristics                          Pilot study                                            Comparative study                        
  ---------------------------------------------------- ------------------------------------------------------ ------------------- -------------------- -------------------
  **Age (years)**                                      Median (range)^a^                                      26 (23--28)         22 (18--40)          28 (22--35)
  **Sex**                                              Male, *n* (%)                                          2 (100%)            7 (53.8%)            5 (55.6%)
  Female, *n* (%)                                      NA                                                     6 (46.2%)           4 (44.4%)            
  **Race**                                             White, *n* (%)                                         1 (50.0%)           11 (84.6%)           7 (77.8%)
  Asian, *n* (%)                                       1 (50.0%)                                              0 (0.0%)            2 (22.2%)            
  Native Hawaiian or Other Pacific Islander, *n* (%)   0 (0.0%)                                               1 (7.7%)            0 (0.0%)             
  Native South American, *n* (%)                       0 (0.0%)                                               1 (7.7%)            0 (0.0%)             
  **Ethnicity**                                        Not Hispanic/Latino                                    NR                  12 (92.3%)           9 (100%)
  Hispanic/Latino                                      NR                                                     1 (7.7%)            0 (0.0%)             
  **Height (cm)**                                      Median (range)[^a^](#t001fn002){ref-type="table-fn"}   181 (176--185)      173 (161--187)       172 (162--180)
  **Weight (kg)**                                      Median (range)[^a^](#t001fn002){ref-type="table-fn"}   74.5 (71.3--77.7)   72.3 (59.4--103.8)   77.9 (54.2--85.5)
  **BMI (kg/m**^**2**^**)**                            Median (range)[^a^](#t001fn002){ref-type="table-fn"}   22.9 (22.7--23.0)   25.3 (20.0--29.7)    26.6 (19.6--31.4)

Table shows only participants who were inoculated with malaria parasites. All data are values recorded at screening.

^a^For the pilot study, values are mean (range) because the median of 2 participants could not be determined.

**Abbreviations**: BMI, body mass index; NA, not applicable; NR, not recorded

In the pilot study, parasitaemia was detectable by qPCR on Day 4 and increased until AS administration on Day 9. Parasitaemia decreased in both participants post-AS administration until recrudescence occurred on Day 11, when DHA/PQP was administered. Parasitaemia did not completely clear after DHA/PQP administration ([S1 Fig](#pmed.1003203.s006){ref-type="supplementary-material"}), with qRT-PCR indicating that persisting parasites included gametocytes ([S5 Table](#pmed.1003203.s015){ref-type="supplementary-material"}). Parasites cleared completely after A/P and PQ administration on Day 26.

In the pilot study, the weighted mean parasite life cycle duration of ART-R parasites prior to AS administration was 46.7 hours (95% confidence interval \[CI\]: 43.8--49.6 hours; [S2 Fig](#pmed.1003203.s007){ref-type="supplementary-material"}), which is longer than the approximately 39 hours previously estimated for ART-S parasites in IBSM studies \[[@pmed.1003203.ref016]\]. Therefore, for the comparative study, ART-R infected participants were inoculated a day earlier than ART-S infected participants, so that parasites were at a similar stage of development in all participants at the time of AS administration.

In the comparative study, parasitaemia increased in both ART-R and ART-S infected participants until AS administration on Day 9 ([Fig 3](#pmed.1003203.g003){ref-type="fig"}). Median parasitaemia prior to AS administration for ART-R infected participants was 71,427 parasites/mL (range 17,611--346,298 parasites/mL) and for ART-S infected participants 31,400 parasites/mL (range 10,625--393,678 parasites/mL). Parasite growth curves indicated that at the time of AS administration both ART-R and ART-S parasites were at a similar stage of development ([S3 Fig](#pmed.1003203.s008){ref-type="supplementary-material"}).

![Individual parasite growth and clearance profiles in the comparative study.\
Parasitaemia of participants enrolled in Cohort 1 (A), Cohort 2 (B), and Cohort 3 (C) of the comparative study, as determined by 18S quantitative PCR. Participants were inoculated with parasites on Day 0 (ART-R) or Day 1 (ART-S) and administered AS on Day 9 (red dashed line). Black arrows represent PQP administration, and purple arrows represent A/P administration. All ART-R infected participants received PQP on Day 11, whereas ART-S infected participants received PQP between Days 15 and 20. PQ was also administered before the end of the study to clear gametocytes (grey arrows). A/P, atovaquone/proguanil; ART-R, artemisinin-resistant; ART-S, artemisinin-sensitive; AS, artesunate; PQP, piperaquine; PQ, primaquine.](pmed.1003203.g003){#pmed.1003203.g003}

In the comparative study, parasitaemia decreased in ART-R infected participants post-AS administration, with recrudescence occurring on Day 11, when PQP was administered ([Fig 3](#pmed.1003203.g003){ref-type="fig"}). Parasitaemia in ART-S infected participants decreased post-AS administration to lower levels than ART-R infected participants ([Fig 3](#pmed.1003203.g003){ref-type="fig"}). Persisting low levels of parasitaemia were observed in ART-S infected participants before recrudescence occurred between Days 11.5 and 16 (median Day 13); PQP was administered for recrudescence ([Fig 3](#pmed.1003203.g003){ref-type="fig"} and [S6 Table](#pmed.1003203.s016){ref-type="supplementary-material"}).

Parasitaemia decreased in all ART-R and ART-S infected participants after PQP administration. Five ART-R infected participants had a second recrudescence of parasitaemia after PQP administration. qRT-PCR indicated that gametocytes were present in all participants ([S5 Table](#pmed.1003203.s015){ref-type="supplementary-material"}). Following A/P and PQ administration ([S6 Table](#pmed.1003203.s016){ref-type="supplementary-material"}), parasites were cleared completely in all participants ([Fig 3](#pmed.1003203.g003){ref-type="fig"}).

In the pilot study, the parasite clearance half-life after AS administration was 5.4 hours ([Table 2](#pmed.1003203.t002){ref-type="table"} and [S7 Table](#pmed.1003203.s017){ref-type="supplementary-material"}). In the comparative study, parasite clearance half-life in ART-R infected participants after AS administration was twice as long than in ART-S infected participants (6.5 hours versus 3.2 hours; *p* \< 0.001; [Table 2](#pmed.1003203.t002){ref-type="table"} and [S7 Table](#pmed.1003203.s017){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003203.t002

###### Parasite clearance slope, log~10~PRR~48~, and parasite clearance half-life after AS administration.

![](pmed.1003203.t002){#pmed.1003203.t002g}

  Parasite clearance parameter                          Pilot study                 Comparative study           *p* value[^a^](#t002fn002){ref-type="table-fn"}   
  ----------------------------------------------------- --------------------------- --------------------------- ------------------------------------------------- ---------
  **Parasite clearance slope (95% CI)**                 −0.056 (−0.062 to −0.051)   −0.046 (−0.048 to −0.045)   −0.096 (−0.100 to −0.091)                         \<0.001
  **Log**~**10**~**PRR**~**48**~ **(95% CI)**           2.70 (2.43--2.97)           2.23 (2.15--2.31)           4.59 (4.38--4.79)                                 \<0.001
  **Parasite clearance half-life \[hours\] (95% CI)**   5.4 (4.9--6.0)              6.5 (6.3--6.7)              3.2 (3.0--3.3)                                    \<0.001

Log~10~PRR~48~ and parasite clearance half-life are transformations of the weighted mean parasite clearance slope.

^a^*p* value is for the comparison of artemisinin-resistant and artemisinin-sensitive infected participants in the comparative study. *p* value was obtained using an omnibus test on weighted mean clearance slope estimates of artemisinin-resistant and artemisinin-sensitive parasites.

**Abbreviations**: AS, artesunate; CI, confidence interval; log~10~PRR~48~, parasite reduction ratio per 48 hours in the logarithmic base 10 scale

During the pilot study, 36 adverse events were reported in 2 participants, whereas 277 adverse events were reported in 22 participants in the comparative study ([Table 3](#pmed.1003203.t003){ref-type="table"}). No serious adverse events were reported. Most adverse events were mild and attributable to malaria. Common adverse events in both studies were headache, pyrexia, myalgia, nausea, and chills ([S8 Table](#pmed.1003203.s018){ref-type="supplementary-material"}). A total of 11 adverse events in ART-R infected participants (*n* = 5) and 2 adverse events in ART-S infected participants (*n* = 1) were related to antimalarial drugs ([S9 Table](#pmed.1003203.s019){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003203.t003

###### Adverse events reported during the studies.

![](pmed.1003203.t003){#pmed.1003203.t003g}

  Adverse events category                                                                                          Pilot study    Comparative study   
  ---------------------------------------------------------------------------------------------------------------- -------------- ------------------- --------------
  **Participants with at least one adverse event**                                                                 2 (100%) 36    13 (100%) 151       9 (100%) 126
  **Participants with at least one adverse event by maximum severity**[^a^](#t003fn002){ref-type="table-fn"}                                          
  Mild                                                                                                             0 (0.0%) 23    1 (7.7%) 116        1 (11.1%) 92
  Moderate                                                                                                         1 (50.0%) 12   9 (69.2%) 30        5 (55.6%) 30
  Severe                                                                                                           1 (50.0%) 1    3 (23.1%) 5         3 (33.3%) 4
  Participants with at least one adverse event related to malaria                                                  2 (100%) 29    13 (100%) 117       9 (100%) 108
  Participants with at least one adverse event related to study drugs                                              1 (50.0%) 4    4 (30.8%) 7         1 (11.1%) 2
  Participants with at least one adverse event related to mosquito feeding[^b^](#t003fn003){ref-type="table-fn"}   NA             6 (46.2%) 6         1 (11.1%) 1
  Participants with a serious adverse event                                                                        0 (0.0%) 0     0 (0.0%) 0          0 (0.0%) 0
  Participants with an adverse event leading to participant discontinuation                                        0 (0.0%) 0     0 (0.0%) 0          0 (0.0%) 0

The table shows only participants who were inoculated with malaria parasites and completed the study.

^a^Number of occurrences (M) of adverse events in this row is not by maximum severity, but total mild, moderate, and severe adverse events.

^b^Mosquito feeding was not performed in the pilot study and was performed in all artemisinin-resistant infected participants and one out of 9 artemisinin-sensitive infected participants in the comparative study.

**Abbreviations**: M, number of occurrences of adverse events; NA, not applicable

Ten severe adverse events were recorded in 7 participants, all related to malaria. Four participants experienced transient falls in white cell counts that were classified as severe: transient leukopenia (ART-R *n* = 1, 1.8 × 10^9^/L, lower limit of normal \[LLN\] = 3.5 × 10^9^/L); lymphopenia ART-R *n* = 1, 0.49 × 10^9^/L, LLN = 1 × 10^9^/L); and neutropenia (ART-R *n* = 2, 0.99 × 10^9^/L, 0.95 × 10^9^/L; ART-S *n* = 1, 0.89 × 10^9^/L; LLN = 1.5 × 10^9^/L). A total of 2 ART-R infected participants and 2 ART-S infected participants had transient increases in alanine aminotransferase (ALT) levels that were classified as severe and peaked at 250 U/L (6.3 × upper limit of normal \[ULN\]), 248 U/L (6.2 × ULN), 247 U/L (8.2 × ULN), and 301 U/L (10.0 × ULN). One ART-S infected participant had an ALT elevation classified as severe concurrent with an elevation in aspartate aminotransferase that peaked at 225 U/L (6.4 × ULN), also classified as severe; no participant had a clinically significant increase in bilirubin.

In the comparative study, 1 ART-S infected participant and 1 ART-R infected participant developed ventricular extrasystoles; both began on Day 9 prior to AS administration. These ventricular extrasystoles were assessed as moderate in severity and possibly related to malaria. Serial electrocardiogram monitoring of the ART-S infected participant showed frequent isolated monomorphic ventricular ectopy, whereas the ART-R infected participant had ventricular bigeminy, trigeminy, and couplets. Serial measurement of troponin I levels ([S10 Table](#pmed.1003203.s020){ref-type="supplementary-material"}) and echocardiography for both participants, as well as cardiac magnetic resonance imaging in the ART-R infected participant, ruled out structural cardiac abnormalities or myocardial damage. Follow-up by a specialist cardiologist of both participants indicated that the ventricular extrasystoles were attributable to unmasking of a predisposition to benign fever-induced tachyarrhythmia. Additionally, 4 ART-R infected participants and 1 ART-S infected participant were noted to have transient prolongation in their QT interval corrected using Fridericia's formula (QTcF) between ≥30 ms and ≤60 ms during the comparative study compared to either the pre-inoculum baseline and/or the pre-PQP baseline (including the ART-R infected participant with ventricular bigeminy; [S11 Table](#pmed.1003203.s021){ref-type="supplementary-material"}). All adverse events, except the 2 cases of ventricular extrasystoles, resolved by the end of the study (pilot study, Day 90; comparative study, Day 55).

Pharmacokinetic parameters of AS and DHA for the pilot study are presented in [S4 Fig](#pmed.1003203.s009){ref-type="supplementary-material"} and [S12 Table](#pmed.1003203.s022){ref-type="supplementary-material"} and for the comparative study in [S5 Fig](#pmed.1003203.s010){ref-type="supplementary-material"} and [S13 Table](#pmed.1003203.s023){ref-type="supplementary-material"}. ART-R and ART-S infected participants in the comparative study showed similar pharmacokinetic profiles ([S5 Fig](#pmed.1003203.s010){ref-type="supplementary-material"}).

Discussion {#sec017}
==========

In this study, we developed the first (to our knowledge) human model of ART-R *P*. *falciparum* malaria. Infection of healthy, malaria-naïve participants with ART-R parasites was safe and well tolerated. ART-R parasites cleared from all participants with available antimalarial drugs. As expected, ART-R parasites took longer to clear than ART-S parasites.

The observed difference in parasite clearance between ART-R infected participants and ART-S infected participants was larger than the 30% difference in mean parasite clearance rates that the study was powered to detect. The longer parasite clearance half-life after a single-dose of AS observed in ART-R infected participants compared with ART-S infected participants (6.5 versus 3.2 hours) agrees with the values reported in malaria patients treated with AS in the Greater Mekong subregion (\>5 hours) \[[@pmed.1003203.ref001]--[@pmed.1003203.ref003],[@pmed.1003203.ref017]\]. These results are in contrast to a recently reported study of splenectomised *Aotus* monkeys infected with either wild-type or ART-R mutant parasites in which no difference in parasite clearance half-life was reported \[[@pmed.1003203.ref018]\].

Parasite clearance after drug treatment is a complex process involving factors such as the mechanism of action of the drug, splenic clearance of erythrocytes containing dead or damaged parasites, and the effect of host immunity. The delayed clearance observed in field ART-R infections could be confounded by these factors \[[@pmed.1003203.ref019]\]. However, our studies used malaria-naïve participants given a single dose of antimalarial drug rules out these confounding effects.

In the comparative study, we inoculated ART-R infected participants a day earlier than ART-S infected participants to account for the longer duration of the parasite life cycle of ART-R parasites, as estimated with the data from the pilot study. By inoculating ART-R infected participants one day earlier, we aimed to administer AS at the same stage of parasite life cycle for both strains. Therefore, the difference in life cycle duration between the 2 strains is not expected to influence the comparison of parasite clearance.

This study was designed to characterise the pharmacodynamic response after a single dose of AS; therefore, we anticipated that recrudescence would occur \[[@pmed.1003203.ref020]\]. The persisting low parasitaemia observed in ART-S infected participants after AS administration could indicate the presence of dormant parasites, which have been previously described in vitro \[[@pmed.1003203.ref021],[@pmed.1003203.ref022]\], or could be a consequence of a fraction of ART-S parasites surviving single-dose AS. Further investigation is required to understand the reason for this persisting low parasitaemia. The recrudescence after PQP administration (960 mg) that occurred in 5 ART-R infected participants was likely due to insufficient drug exposure to kill all parasites rather than to drug resistance because the ART-R parasite strain tested PQP-sensitive by in vitro assay.

The adverse events observed in this study were in line with previous IBSM studies with ART-S parasites conducted at our site and elsewhere \[[@pmed.1003203.ref006]--[@pmed.1003203.ref009]\]. The transaminase elevations were transient and asymptomatic and were not associated with clinically significant elevations in bilirubin. Similar liver function changes have been reported in previous IBSM studies \[[@pmed.1003203.ref008]\] and sporozoite challenge studies \[[@pmed.1003203.ref023]\], as well as in natural malaria infections \[[@pmed.1003203.ref024],[@pmed.1003203.ref025]\], indicating these elevations are likely due to the inflammatory process in malaria infection.

No evidence of myocardial damage was detected as a cause of the 2 cases of ventricular extrasystoles that occurred during the comparative study. After comprehensive investigations, both adverse events were attributed to undiagnosed predispositions to cardiac arrhythmias that were unmasked by the febrile illness. Cardiac events with associated myocardial damage have been reported in malaria VIS with sporozoites \[[@pmed.1003203.ref026],[@pmed.1003203.ref027]\]. Furthermore, serendipitous detection of benign cardiac arrhythmias has been documented in early phase clinical trials \[[@pmed.1003203.ref028],[@pmed.1003203.ref029]\].

The main limitation of this study is that the ART-R and ART-S parasite strains do not share the same genetic background. An optimal strain for comparison may have been the ART-S parasite generated by back mutation of the ART-R strain \[[@pmed.1003203.ref004]\]. Furthermore, the R539T genotype has been outcompeted by other genotypes such as C580Y \[[@pmed.1003203.ref030]\]. However, observations from field studies have demonstrated that parasite clearance half-life in patients carrying either the R539T or the C580Y mutation are similar \[[@pmed.1003203.ref031]\]. Therefore, we believe that our model is suitable to investigate drugs effective against ART-R parasites. Furthermore, both the R539T and the C580Y strains are widely distributed across the Greater Mekong subregion \[[@pmed.1003203.ref031],[@pmed.1003203.ref032]\]. Another limitation of the study is that our results are difficult to generalize to other populations. All the participants in these studies were malaria naïve, and therefore their response to malaria infection may be different to patients in endemic areas, where patients may have different levels of immunity to malaria. In addition, levels of parasitaemia are lower in VIS than in clinical malaria, which further hinders generalisability. Nevertheless, despite these limitations, the delayed clearance profile of ART-R parasites after AS observed in these studies is comparable to observations from field studies \[[@pmed.1003203.ref001]--[@pmed.1003203.ref003],[@pmed.1003203.ref017]\].

This is the first time that a *Plasmodium* spp. strain has been isolated from a patient with clinical malaria, used to manufacture a master cell bank in vitro in compliance with good manufacturing practice, and inoculated into healthy participants. We have shown that this approach is safe and can be used for VIS with other parasite strains for drug development.

In conclusion, we developed the first (to our knowledge) human model of ART-R *P*. *falciparum* malaria. Although based on a relatively small sample size, results indicate that this ART-R IBSM model is safe and replicates the delayed parasite clearance phenotype documented in the field. The ART-R IBSM model will be a powerful tool to test the efficacy of candidate antimalarial drugs against ART-R infections.
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\[LINK\]
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Academic Editor comments:

This is a descriptive study but readers may be helped if the authors could formulate a clear research question which could be presented at the end of the introduction?

Editor comments:

Title: Please revise your title according to PLOS Medicine\'s style. Would it be more accurate to call your study 2 phase 1 trials? Please add the country setting.

Abstract -- Please add summary demographic information including mean age; Please add information regarding country setting and towns and recruitment.

Main text -- Please ensure refs are in square brackets before punctuation.

Data -- note an author cannot be a point of contact for data requests. Please provide another contact such as a data manager.

Throughout the text there is a lack of information about the locations of these trials as well as where recruitment was. Please provide.

Please use sections and paragraphs in the CONSORT as page numbers can change during revision and formatting.

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Data -- you say some restrictions will apply, then say all data is available in the MS and Supp Files. Please state what data is available and what is not and why.

Abstract -- this should be formatted with 3 sections: Background, Method and Findings, Conclusion. Please format accordingly.

Abstract -- use months as well as years for recruitment and tell us the cities / regions where recruitment took place, if known; Please use 95% Cis as well as p values for all quantifiable data (both here and throughout the manuscript); Please ensure summary demographic information is provided, including gender ratio and mean age and number of smokers, etc; Please provide -- as the last sentence of the 'Methods and Findings' section a sentence on the limitations of the study;

At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

Refs in main text, these need to be presented in square brackets and not using superscript.

In the main text where you use 95%Cis, please also add p values.

Please include line numbers on your revised version.

Please be careful of deriving cause where non can be drawn as this is not a trial: "Our data provide evidence..." and "In summary, our study provides evidence that obesity, even without metabolic syndrome..."

Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references> (noting remove ital font specifically)

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please ensure that the study is reported according to the STROBE guideline, and include the completed STROBE checklist as Supporting Information. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).\"

The STROBE guideline can be found here: <http://www.equator-network.org/reporting-guidelines/strobe/>

When completing the checklist, please use section and paragraph numbers, rather than page numbers.

Comments from the reviewers:

Reviewer \#1: To the authors,

The manuscript \"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: a randomised volunteer infection study\" by Watts et al describes with full details the establishment of an induced blood stage malaria model in human volunteers and the results they obtain in two assays.

The manuscript is well written, the study is nicely designed and incorporates all the necessary prerequisites for the selection of the volunteers, the monitoring of the infections and the clinical management of the patient.

Some minor amendments / precisions could give some valuable points:

\- A justification of why from the beginning IBSM was preferred to sporozoites induced infections that are more close to natural ones?

\- While assessing parasitaemia by 18S qPCR is very precise, a justification of why not making blood film concurrently could be useful particularly to correlate with stages present and their development.

\- The use of the name \"K13 parasite\" all along the study sounds inadequate and could be misleading since all P. falciparum (including the 3D7 use for comparison) harbour the K13 gene. The use another name or the real strain or isolate name could be preferable.

\- The production of the master cell bank references the 3D7 strain. No precision is given for the production of ART-R parasite MCB and the study only mentioned as a limitation that both parasites have different genetic background. Was the same method (GAP) applied to the production of the MCB for the ART-R parasite? Which gene have been targeted? Could the authors give precision about ART-R parasite MCB such as parasite stages also represented by 96% of rings, presence of schizonts and gametocytes, parasitaemia?

\- The ART-R strain used was R539T while the authors acknowledged that this strain have been outcompeted by some other such as the C580Y, they could also highlight that this strain is widely distributed in SEA with adequate reference.

\- The listed serological tests include: HBs Ag, anti-HBc Ab, anti-HCV Ab, anti-HIV1 and anti-HIV2 Ab... Despite stringent selection criteria, did any serological tests for Malaria were performed?

\- Gametocytaemia for both macro- and microgametocytes was tested by stage specific qRT-PCR and the results sounds promising for transmission experiments. Transmission experiments to mosquitoes were attempted as exploratory study but only very limited information is provided, and as stated \"the results will be shared separately... With no need to provide the full details and results about these experiments it is highly desirable to state if the transmission was achieved or not, this will help validate the model presented.

\- It would be good to present, in table format, the clinical biochemistry and haematology parameters recorded along the experiments with reference values and highlighting the abnormal ones.

Overall, it is an impressive study and an interesting manuscript that contribute to the development of safe and useful human malaria infection models. Thank you.

Reviewer \#2: In the proposed document, the authors report the results of a human challenge experiment. I have restricted my comments to the statistical analyses. The methods require additional detail.

The authors calculate \'The weighted mean of the parasite clearance slope\', however, it is not clear what the parasite clearance slope is and what the weights are. This should be clarified.

The authors refer to an \'omnibus test\', however no reference is made. A brief description of this test should be provided to help the non-specialist reader.

The authors conduct a \'sine-wave growth model\' to model the viral titers (I believe). The authors should set out why this model was chosen (I presume for the sinusoidal nature of the dynamics). It would also be useful to demonstrate the fit of their model (e.g., plot the observed versus fitted average values).

The authors should clarify what the weights are for the sine-wave growth model.

Similarly, the authors state that \'Pharmacokinetic parameters were determined by non-compartmental analysis, however, it is not clear what a non-compartmental analysis represents. The authors should describe what they mean by this and clarify exactly what parameters are being estimated.

Reviewer \#3:

This is an impressive study of great importance. Human model for artemisinin resistant malaria could be valuable for a variety of reasons, including (but not limited to) controlled studies of new antimalarials. I have a few small comments, questions, and clarifications that should be addressed.

Major critique:

The limitations should be more comprehensively considered and explained. As I\'ve already stated, this is an impressive amount of work. Pointing out potential limitations to this work does not detract from the quality of work.

Currently, the only limitation that the authors discuss is related to the different genetic background between 3d7 and the k13 strain that they chose for this study. No explanation is given for why they chose the strain that they did. No comments are given about testing to see if their hypothesis (that they would have the same results if using a different strain) is true.

No discussion is given about sample sizes or generalizability/representativity of the study population to other populations.

On page 19: \"However, our studies used malaria naïve participants given a single dose of antimalarial drug, which rules out these confounding effects.\" Some immunity is inherited rather than acquired, and immunity to malaria in general is not well understood. Were there any tests for blood cell variations among participants? Given that immunity is complex, and not perfectly understood, it is a bit too strong of a statement to suggest that having malaria naïve participants completely accounts for any possible confounding from immunity. Also, the inclusion criteria appears to limit potential malaria exposure to the last year. While some types of malaria immunity are short lived, immunological markers for malaria (msp, csp, etc.) can last for a very long time (years and possibly decades).

Minor critiques:

Title: Why is the term \"volunteer infection study\" used rather than \"human challenge study\"? Are they not the same? The latter is more commonly used and would be more clearly understood by most infectious disease specialists.

Introduction: \"This drug resistant phenotype is linked to specific mutations...\" It would be a bit more accurate to describe this as mutations in a specific genome region, rather than specific mutations, since there are several different mutations in the kelch region that are associated with the phenotype of delayed parasite clearance.

In the final paragraph of page 4, it would help if there was a sentence explaining that both the pilot and the comparative (second) study are being presented here. It becomes clear in the methods and results sections, but it would be good to state up front that this manuscript presents the results from both a pilot study and a follow-up study. A simple: \"Here we present results from... \" type statement here would work.

Why was the R539T mutation chosen? There are others of higher concern...

Page 6: It is a bit confusing to have the K13 inoculants on day 0 and 3d7 inoculants on day 1. Later you give a brief explanation for why, but it would add some clarity if it was explained here.

Page 9: The pharmacokinetic parameters for artesunate and DHA should be explained. Some readers will not immediately recognize the abbreviations.

Page 12: Regarding the difference in parasite life cycle duration, which led to starting the K13 infected participants a day earlier... this deserves at least a statement or two in the conclusion. Also, if life stages are normally at different lengths, does this not influence the comparison of the 3d7 and the K13 resistant parasitemias? Or is this accounted for with the use of the mixed effects model? Please explain.

Page 12: Any explanation for the massive difference in parasitemia between the K13 lineage and 3d7 (with parasitemia over 2 times larger)?

Page 14: This isn\'t a minor point, but consider giving a quantitative value rather than stating that clearance was \"significantly longer\" - for example, it looks like clearance was twice as long for the k13 resistant infected participants when compared to the 3d7 infected participants.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003203.r003
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Dear Dr. McCarthy,

Thank you very much for re-submitting your manuscript \"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia\" (PMEDICINE-D-20-00295R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by the original reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 10 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

In the attached protocol documents, some of the authors are listed as having positions with \"Q Pharm\", which is apparently a company (CRO). If they have been paid by Q Pharm, I think this should be included in the competing interest statement.

The data statement needs to be updated to note how the authors will make the aggregate data available; also please remove the author contact as this is not permitted.

Line 51 an elsewhere please add in to our knowledge re \"the first\"

Line 146 -- can you clarify what you mean by 'which was finalised before the data was locked for analysis.'

Please remove all trademark signs

It seems from the protocol that the volunteers received money; Please mention this in the methods section

If I understand correctly the authors cannot rule out a small risk of blood-borne pathogen transmission in this system, and they could mention this in the methods section.

\- At line 379, we learn that 7 participants had \"severe adverse events related to malaria\". This seems to have been missed in the abstract and author summary which note that there were \"no serious adverse events\". Please amend.

Please ensure the abstract is accurate on safety events. Please quote the severe adverse events up-front (including the 2 cardiac events, incidentally) and noting that these were not clinically serious (in their assessment)

Where the authors claim that the method can be \"safely used\", they can perhaps modify this by acknowledging the small size of their study

Please adjust statistics to style: p\<0.0001 -\> p\<0.001 in abstract and at least one table

In the revised doc, when resubmitting, please add the marked up version as a Supp file instead of including with the clean doc in the main file.

Comments from Reviewers:

Reviewer \#1: Dear authors and editors,

The revision of the manuscript now titled \"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia\", presents an impressive piece of work based on a large amount of data and detailed studies.

Encompassing, detailed answers to the reviewers\' comments and the editorial requests, this revision has definitely gains in clarity, precision and readability.

A single minor comment: since the study is based in Australia in the \"theoretical risk zone\" for autochthonous Babesia microti, did serology for Babesia was performed in the volunteers accounting that Babesia is often asymptomatic and some cross-protective immunity exists with Plasmodium? This could be mentioned.

Overall, this a convincing study presenting a new and valuable tool in the field of Plasmodium falciparum artemisinin-resistance. This tool will definitely be useful for further studies and has the potential to accelerate the development and evaluation of new anti-malarial drugs efficient against ART-R parasites which urgently needed. I will be happy to it published.

Reviewer \#2: I have no further comments

Reviewer \#3: The authors have satisfactorily addressed all of my questions and concerns.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003203.r005

Author response to Decision Letter 2

16 Jul 2020

###### 

Submitted filename: Watts_et_al_responses_17Jul20.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003203.r006
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21 Jul 2020

Dear Prof. McCarthy,

On behalf of my colleagues and the academic editor, Dr. Lorenz von Seidlein, I am delighted to inform you that your manuscript entitled \"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia\" (PMEDICINE-D-20-00295R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: REW, AO, LM, LW, ANA, LC, MR, ZP, KAC, CP, and JSM are employees of the study sponsor QIMR Berghofer Medical Research Institute; SC and JJM are employees of Medicines for Malaria Venture which provided funding for the study.
